Cheetah Cell Therapeutics

Cheetah Cell Therapeutics is a biotechnology company focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies for oncology and autoimmune diseases. The company utilizes its proprietary Cheetah-CAR platform to engineer T-cells with enhanced persistence, reduced exhaustion, and improved safety profiles compared to traditional CAR-T products. By optimizing the metabolic and signaling pathways of the engineered cells, Cheetah Cell Therapeutics aims to overcome the limitations of current cell therapies in treating solid tumors and refractory hematologic malignancies. Their pipeline includes several early-stage programs targeting validated antigens such as CD19 and BCMA, with a focus on rapid manufacturing and improved patient outcomes.